## Editorials

**Sjögren Syndrome and Work Disability**  
A. Dumusc, S.J. Bowman  
133

**Vasculitis Around the World: Epidemiologic Insights into Causality and a Need for Global Partnerships**  
S. Banerjee, P.C. Grayson  
136

**Back to the Future of Rheumatology**  
Y.H. Pigott, C.M. Rodrigo, E.D. Silverman  
140

## Rheumatoid Arthritis

**Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with RA Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study**  
G. Jones, T. Wallace, M.J. McIntosh, L. Brockwell, J.J. Gómez-Reino, A. Sebba  
142

**Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with RA**  
K. Shidara, A. Nakajima, E. Inoue, et al  
147

**Disease Characteristics and RA Development in Patients with Early Undifferentiated Arthritis: A 2-year Followup Study**  
G.H. Brinkmann, E.S. Norli, T.K. Kvien, et al  
154

**Rituximab Retreatment in RA in a Real-life Cohort: Data from the CERERRA Collaboration**  
K. Chatzidionysiou, E. Lie, G. Lukina, et al  
162

**Explanatory Style in Patients with RA: An Unrecognized Predictor of Mortality**  
A.D. Crowson, R.C. Colligan, E.L. Matteson, J.M. Davis III, C.S. Crowson  
170

## Psoriatic Arthritis

**Changes in Treatment Patterns in Patients with PsA Initiating Biologic and Nonbiologic Therapy in a Clinical Registry**  
P.J. Mease, T. Lesperance, M. Liu, et al  
184

**Mapping the Effect of PsA Using the International Classification of Functioning, Disability and Health**  
193

## Systemic Lupus Erythematosus

**Spatial Working Memory Impairment in Patients with Non-neuropsychiatric SLE: A Blood-oxygen-level Dependent Functional MRI Study**  
C.M. Zhu, Y. Ma, L. Xie, et al  
201

## Sjögren Syndrome

**Work Disability in Newly Diagnosed Patients with Primary Sjögren Syndrome**  
T. Mandl, T.S. Jørgensen, M. Skougaard, P. Olsson, L.E. Kristensen  
209

## Vasculitis

**Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts**  
S. Furuta, A.N. Chaudhry, Y. Arimura, et al  
216

## Myositis

**A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome**  
R. Aggarwal, N. Dhillon, N. Fertig, D. Koontz, Z. Qi, C.V. Oddis  
223

## Pediatric Rheumatology

**Predicting Which Children with JIA Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort**  
J. Guzman, A. Henrey, T. Loughin, et al, on behalf of the ReACCh-Out Investigators  
230

---

**Contents continued on page xvi**
Other Arthritides
Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study
M.C. Miceli, A. Zoli, G. Peluso, S. Bosello,
E. Gremese, G. Ferraccioli .......................... 241

Medical Education
Stand Up and Be Counted: Measuring and Mapping the Rheumatology Workforce in Canada
C.E. Barber, L. Jewett, E.M. Badley, et al ............ 248

Images in Rheumatology
Transient Osteoporosis of the Hip in a Middle-Aged Male Construction Worker
T.S. Kwok, T.N. Ruban, M. Steirman .................. 258

Correspondence
Patients with RA in Remission While Receiving Etanercept Plus Methotrexate Therapy May Require Adjustment of Dosing Regimen When Switched to Methotrexate Monotherapy
B. Bannwarth ................................. 259

Letters
Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of JIA-associated Uveitis
E. Quesada-Masachs, C. Modesto Caballero .......... 260
Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with RA: Observational Data in a Real-life Setting
E.G. Favalli, A. Becchioli, P.L. Meroni ................ 262

Correction
Triage of Rheumatology Referrals Facilitates Wait Time Benchmarks
C. Farrer, L. Abraham, D. Jerome, J. Hochman, N. Gakhal ............................................. 263

Meetings in Rheumatology ............................ x